Franklin Resources Inc Gemini Therapeutics, Inc. Transaction History

Franklin Resources Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$1.22 - $1.73 $1.31 Million - $1.85 Million	-1,071,790 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$1.29 - $3.08 $1.86 Million - $4.44 Million	-1,440,983 Reduced 57.35%	1,071,790 $1.49 Million
Q3 2021 Nov 12, 2021	BUY	$3.3 - $6.32 $2.99 Million - $5.73 Million	907,173 Added 56.5%	2,512,773 $10.2 Million
Q2 2021 Aug 13, 2021	BUY	$6.32 - $14.02 $6.99 Million - $15.5 Million	1,105,600 Added 221.12%	1,605,600 $10.4 Million
Q1 2021 May 13, 2021	BUY	$11.32 - $18.0 $5.66 Million - $9 Million	500,000 New	500,000 $6.78 Million

2.44M

Ticker GMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,244,500
Market Cap $1.05B
Description
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 ...

Get notified when there are updates to the investment portfolio of Franklin Resources Inc, based on Form 13F filings with the SEC.

Stay updated on Franklin Resources Inc with notifications on news.